discovery passport
Bern, Switzerland and Boston, February 20, 2024 (Globe Newswire) — Ikerian AG and RetinAI Inc. US (“RetinAI”), a leader in developing software solutions for image processing and artificial intelligence (AI) in ophthalmology. has been launched. RetinAI Discovery® For clinic use (“Discovery”), there are two product versions addressing the needs of ophthalmologists and optometrists.
Discovery for Clinics and its expert-grade AI models are designed to accelerate and enhance clinical decision-making workflows, remote ophthalmology management, referral decisions, and patient management to create data efficiency and enhance clinic decision-making. I am.
Vendor-neutral multimodality platform harmonizes, aggregates, and connects large datasets on a single cloud-based data repository. The data is then automatically analyzed using RetinAI’s CE-marked and Research Use Only (RUO) AI algorithms to speed treatment decisions based on AI biomarkers. AI models can be processed in DICOM and other formats for OCT and fundus imaging.
Both the ophthalmology and optometry versions of Discovery for Clinics include progression analysis that tracks trends in outcomes and provides patients with powerful visualization of disease progression. The platform connects healthcare professionals and patients with Discovery Passport™. Discovery Passport™ is a feature that allows physicians to securely share data and remote surveys with patients, increasing patient engagement and ultimately continuing the quality of patient care in and out of the clinic. Both versions of the platform support referral networks and clinical trial participation through real-world data (RWD) collection, allowing clinics to create additional service opportunities.
In addition to these tools, the ophthalmology version features the RUO AI model for more detailed analysis of geographic atrophy and the ability to examine future atrophy progression through a predictive progression model.
“Discovery for Clinics is a powerful tool that provides access to data for physicians as well as patients, providing enhanced AI-powered data insights to optimize outcomes and treatment.” said Dr. Carlos Schiller, CEO and co-founder of Ikerian, RetinAI’s parent company.
Comments on Discovery for Eye Clinics “We are thrilled to be able to provide this new treatment to our patients,” said Marion R. Monk, Ph.D., MD, professor, FEBO Senior Retinal Physician at Associate Professor Augenarzt-Praxisgemeinschaft Gutblick AG. “RetinAI Discovery”® Fast volumetric AI analysis of OCT images and intuitive progression graphs also provide new insights into eye diseases, allowing users to extract clinical insights faster based on existing AI technology blocks. Ta. ”
Comments on Discovery for Optometry Clinics Dr. Trusit Dave, BSc (Hons), DipTp (IP), FAAO, MCOptom, Professor Cert Galuc said: “I used RetinAI Discovery® We found it to be easy to use and provide useful metrics for AMD, especially for analyzing AMD-related biomarkers to make better patient referral decisions. ”
About U.S. RetinAI Inc. and Ikerian AG www.retina.com
Founded in 2017, Ikerian AG (formerly RetinAI Medical AG) and its subsidiary RetinAI US Inc. use advanced machine learning and computer vision to accelerate clinical, research, and pharmaceutical workflows globally. We develop software solutions. RetinAI builds tools to collect, organize, and analyze health data from the eyes to help healthcare professionals make faster and better decisions in the medical field. RetinAI’s international team leverages its clinical, technical, and scientific expertise to accelerate the transition from reactive to preventive medicine for serious eye diseases.
Follow us on LinkedIn https://www.linkedin.com/company/retina/
About RetinAI Discovery®
RetinAI Discovery® (“discoveryDiscovery is a software platform that enables faster, right decisions based on evidence, AI-driven insights, automation and data. Discovery is a modular, certified (FDA – 510(K) / CE – MDR) ) is a medical imaging and data platform that operates through a web browser on the cloud and enables precise analysis with proprietary AI models and the transfer of patient-linked medical data to devices, data sources, and decision-making. Connect in a seamless and secure way to understand the entire disease trajectory and facilitate decision-making for better patient care.
RetinAI powers discovery for clinics through distributors in Europe.
For more information, please contact us below.
at work
RetinAI Inc US – info@retina.com
Dr. Carlos Schiller, CEO – Ikerian AG carlos@retinai.com
Media inquiries
Sue Charles, Charles Consultants – sue@charles-consultants.com +44 (0)7968726585
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/124f59ad-8922-4363-811b-9e5d402949ca.
